How have RVV shares performed in 2024?

Revive Therapeutics' stock was trading at C$0.08 at the start of the year. Since then, RVV shares have increased by 0.0% and is now trading at C$0.08. View the best growth stocks for 2024 here .

When is Revive Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024. View our RVV earnings forecast .

What other stocks do shareholders of Revive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revive Therapeutics investors own include Heat Biologics (HTBX) , Green Organic Dutchman (TGOD) , Aurora Cannabis (ACB) , CytoDyn (CYDY) , Genprex (GNPX) , iBio (IBIO) , Sorrento Therapeutics (SRNE) , Workhorse Group (WKHS) , Acasti Pharma (ACST) and Anavex Life Sciences (AVXL) .

How do I buy shares of Revive Therapeutics?

Shares of RVV stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

CVE:RVV

Revive Therapeutics (RVV) Stock Price, News & Analysis

→ This company has increased its dividend every year for 54 years (From DTI) (Ad)

Free RVV Stock Alerts

C$0.08

+0.01 (+14.29%)

(As of 07/22/2019)

Compare

Today's Range: C$0.08
▼
C$0.09
50-Day Range: C$0.08
▼
C$0.08
52-Week Range: C$0.07
▼
C$0.25

Volume: 212,852 shs
Average Volume: 93,085 shs
Market Capitalization: C$5.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Revive Therapeutics alerts:

Ad DTI

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

Click here to get them (for Free).

About Revive Therapeutics Stock (CVE:RVV)

Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada.

RVV Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RVV Stock News Headlines

April 18, 2024 | markets.businessinsider.com

Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product

March 27, 2024 | finanznachrichten.de

Revive Therapeutics Ltd.: Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID

April 18, 2024 | WealthPress (Ad)

Chances are you know the firms on this list

These are the entities that can buy MILLIONS of shares in a single day… I’m talking about huge orders that literally move the share price 1%, 2%, even 5% or more in the process. Why am I showing you that list? Well, because if you have a way to successfully detect which stocks these elite traders are likely buying in real time… All you have to do is ride the coattails of their massive orders and you can target endless trading opportunities without leaving your money exposed to the markets for too long. And in case you didn’t already know…

March 27, 2024 | finance.yahoo.com

Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID

March 19, 2024 | finanznachrichten.de

Revive Therapeutics Ltd.: Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID

March 19, 2024 | markets.businessinsider.com

Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID

March 12, 2024 | finanznachrichten.de

Revive Therapeutics Ltd.: Revive Therapeutics Provides Corporate Update

March 12, 2024 | financialpost.com

Revive Therapeutics Provides Corporate Update

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

February 26, 2024 | markets.businessinsider.com

Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110

February 1, 2024 | markets.businessinsider.com

Revive Therapeutics Explores the Use of Bucillamine for Long COVID

January 31, 2024 | markets.businessinsider.com

Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500

January 24, 2024 | financialpost.com

Revive Therapeutics Ltd. Announces Offering of Up to $3 Million

January 16, 2024 | tmcnet.com

Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada

January 10, 2024 | finanznachrichten.de

Revive Therapeutics Ltd.: Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine

January 10, 2024 | markets.businessinsider.com

Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine

January 8, 2024 | msn.com

Travere Therapeutics expects Q4 net product sales from continuing operations to be about $40M

December 20, 2023 | markets.businessinsider.com

Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders

December 18, 2023 | markets.businessinsider.com

Revive Therapeutics To Work With Attwill For Development Of Lyophilized Formulation Of Bucillamine

December 18, 2023 | financialpost.com

Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine

October 17, 2023 | markets.businessinsider.com

Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure

October 17, 2023 | markets.businessinsider.com

Revive Therapeutics Agrees With DRDC To Evaluate Bucillamine For Nerve Agent Exposure

October 11, 2023 | finanznachrichten.de

Revive Therapeutics Ltd.: Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development

October 11, 2023 | tmcnet.com

Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development

September 28, 2023 | ft.com

Italy turns to Kyrgyz shepherds to revive Sardinian farming

August 22, 2023 | finanznachrichten.de

Revive Therapeutics Ltd.: Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development

August 22, 2023 | stockhouse.com

Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development

See More Headlines

Receive RVV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/18/2024
Next Earnings (Estimated): 6/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: CVE
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: CVE:RVV
CUSIP: N/A
CIK: N/A
Web: www.revivethera.com
Phone: +1-905-6055535
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.14
Quick Ratio: 6.03

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: C$0.03 per share
Price / Cash Flow: 3.18
Book Value: C$0.02 per share
Price / Book: 4.21

Miscellaneous

Outstanding Shares: 72,411,000
Free Float: N/A
Market Cap: C$5.79 million
Optionable: Not Optionable
Beta: N/A

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Craig Leon (Age 51)
Chairman & CEO
Mr. Fabio Chianelli (Age 41)
Pres & Director
Mr. Carmelo Marrelli C.A. (Age 48)
C.P.A., CPA, B.Comm., CA, CGA, ACIS, Chief Financial Officer

Key Competitors

View All Competitors

Insiders

RVV Stock Analysis - Frequently Asked Questions

How have RVV shares performed in 2024?: Revive Therapeutics' stock was trading at C$0.08 at the start of the year. Since then, RVV shares have increased by 0.0% and is now trading at C$0.08.
View the best growth stocks for 2024 here.
When is Revive Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024.
View our RVV earnings forecast.
What other stocks do shareholders of Revive Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Revive Therapeutics investors own include Heat Biologics (HTBX), Green Organic Dutchman (TGOD), Aurora Cannabis (ACB), CytoDyn (CYDY), Genprex (GNPX), iBio (IBIO), Sorrento Therapeutics (SRNE), Workhorse Group (WKHS), Acasti Pharma (ACST) and Anavex Life Sciences (AVXL).
How do I buy shares of Revive Therapeutics?: Shares of RVV stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (CVE:RVV) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial